Action GILD GILEAD SCIENCES, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Gilead Sciences, Inc.

Actions

GILD

US3755581036

Marché Fermé - Nasdaq
Autres places de cotation
 22:00:00 06/06/2024 		Varia. 5j. Varia. 1 janv.
63,84 USD -0,06 % Graphique intraday de Gilead Sciences, Inc. -0,37 % -21,19 %
06/06 Gilead déclare que les données relatives à l'association du bulevirtide et du PegIFN sont "supérieures" à celles de la monothérapie au bulevirtide ; le taux d'ARN du VHD indétectable est de 46%. MT
06/06 Gilead Sciences, Inc. Annonce des données de l'étude ouverte de phase 2b MYR204 CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Combination therapy may hold potential for severe viral hepatitis
Gilead's Seladelpar Demonstrated a Sustained and Consistent Long-Term Efficacy and Safety Profile in Primary Biliary Cholangitis
Gilead Says Bulevirtide With PegIFN Data 'Superior' to Bulevirtide Monotherapy; Achieves 46% Rate of Undetectable HDV RNA
Gilead Announces New England Journal of Medicine Publication of Data that Demonstrate Bulevirtide with PegIFN Achieved Post-Treatment Undetectable HDV RNA
Gilead Sciences, Inc. Announces Data from the Phase 2b MYR204 Open-Label Study
Johnson & Johnson Submits Supplemental New Drug Application to U.S. FDA Seeking Expanded Pediatric Indication for HIV-1 Therapy PREZCOBIX
Gilead Sciences Says Investigational Chronic Liver Disease Drug Shows 'Sustained Efficacy' in Long-Term Trial
Gilead’s Seladelpar Demonstrated a Sustained and Consistent Long-Term Efficacy and Safety Profile in Primary Biliary Cholangitis
Gilead Sciences, Inc. Announces Two-Year Interim Results from the Ongoing Assure Study of Investigational Seladelpar for the Treatment of Primary Biliary Cholangitis, A Rare, Chronic Inflammatory Liver Disease
Sector Update: Health Care Stocks Rise Late Afternoon
Sector Update: Health Care Stocks Rise Tuesday Afternoon
Gilead Sciences Agrees to $40 Million Settlement of Federal TDF Lawsuit
Gilead Sciences : Statement on Agreement in Principle to Resolve Federal TDF Litigation
Gilead Sciences Unit Says Tecartus Improves Overall Survival in Leukemia, Yescarta Well-Tolerated in Lymphoma
Kite’s Tecartus® Demonstrates Sustained Overall Survival in Adult Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
Kite?S Tecartus® Demonstrates Sustained Overall Survival in Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
Encouraging New Data Presented on Kite’s Yescarta® for Relapsed/Refractory Central Nervous System Lymphoma
Kite Announces Data from A Pilot Study in Collaboration with Dana-Farber Cancer Institute
Gilead Sciences, Arcus Biosciences's Colorectal Cancer Combination Therapy Shows Promise
Gilead and Arcus Announces Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-Line Metastatic Colorectal Cancer
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action GILD
  4. Actualités Gilead Sciences, Inc.
  5. Autres langues